New molecules discovered that block cancer cells from modifying cell DNA

Oct 11, 2007

Researchers have discovered new small molecules that may prevent prostate cancer cells from turning off normal genes in a process that transforms normal cells into cancer cells. This significant discovery in the field of epigenetics has immediate implications in the development of new diagnostic tests and cancer medications. The findings were presented today at the Prostate Cancer Foundation’s annual Scientific Retreat.

pigenetics refers to changes to genes other than changes to the DNA sequence itself, such as the addition of molecules to the DNA strand. While the development of cancer can arise from defective or mutated genes, it can also arise from these changes that can actually prevent a cell from acting as it should. Cancer cells exploit this process, putting some genes in “cold storage” or “turned off” by modifying the cell DNA in a process known as methylation.

Lead researcher William Nelson, M.D., Ph.D., Professor of Oncology and Urology at the Johns Hopkins Kimmel Cancer Center, explained the findings. “One of the proteins in the cell that triggers this process is called a methyl-CpG binding protein, or MBD. We have discovered an antagonist of MBD2 that keeps this protein from binding to methylated genes. If the protein can’t bind to the gene, then it can’t keep the gene ‘turned off’ and the gene is turned back on – able to act in the way it is supposed to.”

Nelson noted that the discovery is particularly exciting because of previous research that shows the importance of being able to alter the methylation process in DNA. When mice were developed without the gene that permits this process, they don’t develop cancer. When the gene is removed from cancer cells, they “turn on” genes again in appropriate ways. “The small molecules that we’ve discovered mimic this process, so they may be very exciting lead candidates for the next generation of drugs that may help restore gene function in prostate cancer,” said Nelson.

“This entire field of exploration has been tantalizing for a decade,” said Nelson, “but has only begun to deliver fruit in just the past couple of years. This mechanism of action permits us to look for much more targeted therapies for prostate cancer, and for other cancers as well, such as breast cancer.”

The promise of this field is evident in the current pipeline of diagnostic and therapeutic products in development. There are diagnostic tests being tested that focus on detecting the methylated DNA, which would permit prostate cancer diagnosis at an earlier stage and in a more precise manner. There is also a first generation of FDA-approved medications that work to reverse the methylation process in cancer cells. They include azacitine (Vidaza) and decitabine (Dacogen), both for the treatment of myelodysplastic syndrome, diseases in which the production of blood cells by the bone marrow is disrupted. Vorinostat (Zolinza) also works to turn back on silenced genes, and is approved for use in cutaneous T cell lymphomas.

Dr. Nelson noted that the Prostate Cancer Foundation funding was essential for the research that resulted in this discovery. “PCF supported our research at a time when it was a very new idea. Their investment permitted us to make critical discoveries that have not only put us along the pathway this field -- hopefully one day resulting in new drugs -- but that also allowed us to secure competitive research funding from the National Cancer Institute,” explained Nelson.

Source: GYMR

Explore further: Hodgkin's lymphoma survivors have higher risk for cardiovascular diseases

Related Stories

Weighing and imaging molecules one at a time

4 hours ago

Building on their creation of the first-ever mechanical device that can measure the mass of individual molecules, one at a time, a team of Caltech scientists and their colleagues have created nanodevices ...

Single cells seen in unprecedented detail

1 hour ago

Researchers have developed a large-scale sequencing technique called Genome and Transcriptome Sequencing (G&T-seq) that reveals, simultaneously, the unique genome sequence of a single cell and the activity ...

How RNA machinery navigates our genomic obstacle course

Apr 24, 2015

Once upon a time, scientists thought RNA polymerase—the molecule that kicks off protein synthesis by transcribing DNA into RNA—worked like a wind-up toy: Set it down at a start site in our DNA and it ...

Detailed structure of human ribosome revealed

Apr 24, 2015

A team at the Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC - CNRS/Université de Strasbourg/Inserm) has evidenced, at the atomic scale, the three-dimensional structure of the complete ...

Cell's protein-making machines shift modes under stress

Apr 23, 2015

Similar to a hybrid car that switches from gas to electric as it drives on major highways and secondary roads, Cornell researchers have discovered that the cell's protein-making machinery, called ribosomes, ...

Improving accuracy in genome editing

Apr 23, 2015

Imagine a day when scientists are able to alter the DNA of organisms in the lab in the search for answers to a host of questions. Or imagine a day when doctors treat genetic disorders by administering drugs ...

Recommended for you

'Chemo brain' is real, say researchers

1 hour ago

UBC research shows that chemotherapy can lead to excessive mind wandering and an inability to concentrate. Dubbed 'chemo-brain,' the negative cognitive effects of the cancer treatment have long been suspected, ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.